



FOR IMMEDIATE RELEASE

Biosensors announces positive results in ongoing studies of the Company's drug-eluting stents

Promising clinical data collected for the BioMatrix[®] Stent; three month animal study data presented for the BioMatrix[®] Freedom[™] Stent

Singapore, 14 February 2007 - Biosensors International Group Ltd. ("Biosensors" or the "Company", Bloomberg: BIG SP) announced today that its two newest drug-eluting stent platforms - the flagship BioMatrix and the newly-developed BioMatrix Freedom - continue to demonstrate promising results in ongoing clinical and pre-clinical testing. New data from studies involving the two devices were presented in recent weeks at separate high-profile conferences in Singapore and Geneva.

BioMatrix

At the 17th Singapore LIVE convention in January, strong clinical results for Biosensors' BioMatrix drug-eluting stent were produced from the BEACON registry, involving 292 patients across nine clinical centres in Singapore, Thailand, India, Malaysia and Indonesia. BEACON is a prospective, multi-centre study that involves a broader patient demographic population with more complex disease and is designed to evaluate the continued safety and efficacy of the BioMatrix drug-eluting stent.

The registry results, presented by Professor Koh Tian Hai, Director of the Singapore National Heart Centre, showed that the registry achieved its primary endpoint with the data indicating a 2.1 percent target lesion revascularization¹ rate at six months. The clinical results demonstrated that BioMatrix is safe and effective in treating higher risk patients undergoing percutaneous coronary intervention.

The six-month clinical results also showed a Major Adverse Cardiac Event ("MACE")² rate of 4.8 percent. This is consistent with the recently-presented 5.9 percent MACE rate in the NOBORI 1 Phase 1 nine-month trial involving the Nobori Stent which also utilizes Biosensors' proprietary antirestenosis Biolimus A9[®] drug and biodegradable polymer. There were no incidents of late thrombosis.

Mr. John Shulze, Biosensors' Chief Technology Officer commented: "The positive BEACON registry results continue to affirm the safety and effectiveness of our BioMatrix Stent, particularly since this registry included a more real-world type of patient population, including a higher proportion of diabetic and hypertensive patients with multivessel disease who are more susceptible to post implantation challenges. We are very confident that BioMatrix will address the real-world challenges faced by cardiologists on a daily basis and deliver the promised results of effectiveness and safety."

BioMatrix Freedom

After three months of implantation in animal studies, the BioMatrix Freedom Stent showed no increase in inflammatory response or reduction in vessel lumen area, in contrast to data shown in the bare metal control group. The data was presented by Dr. Renu Virmani, Medical Director of CV Path, a Gaithersburg, Maryland-based independent pathology laboratory, at the 14th International LDDR conference held in Geneva in early February.

BioMatrix Freedom features the Company's newest drug-eluting stent advancements whereby its proprietary anti-restenosis Biolimus A9 drug is directly applied onto the stent's modified outer surface and this eliminates the need to use polymers to release the drug. BioMatrix Freedom was first implanted in humans during the Transcatheter Cardiovascular Therapeutics conference in October 2006.

¹ Target vessel revascularization measures any clinically-driven repeat percutaneous revascularisation or surgical bypass of the original target lesion or any segment of the coronary artery containing the target lesion.

² Major Adverse Cardiac Event is a measure of the percentage of patients who died, suffered a heart attack or needed repeat procedure(s) post stent implantation.

MORE-MORE-MORE

Biosensors announces positive results in ongoing studies of the Company's drug-eluting stents

Page 2-2-2

Dr. Virmani, who was commissioned by Biosensors to evaluate this coating technology, also evaluated three and six-month animal data on Biosensors' proprietary Biolimus A9-eluting biodegradable PLA polymer used in its flagship BioMatrix drug-eluting stent. The results showed that both sets of data were equally safe and effective in these extended animal implant tests.

Commenting on the overall positive findings on both the BioMatrix and BioMatrix Freedom drug-eluting stents, Mr. Chua Kee Lock, President said: "Positive new scientific evidence presented at the two separate conferences have independently reinforced the safety and effectiveness of both the Company's drug-eluting stent platforms. We are confident that as BEACON and the other clinical trials progress in the months ahead, the data will be confirmatory and equally encouraging. We firmly believe that our technology platforms are viable alternatives to currently-available first generation drug-eluting stent solutions."

##End of Release##

Media Contact

Biosensors International Group

Ms Tina Lim, Executive, Corporate Communications

Tel: (65) 6213 5712

Email: media@biosensors.com

Media Relations / Investor Relations Firm

United States

Allen&Caron Inc.

Mr. Matt Clawson

Executive Vice President, Investor Relations

Tel: (1) 949 474 4300

Email: matt@allencaron.com

About Biosensors International Group, Ltd

Biosensors develops, manufactures and markets innovative medical devices used in interventional cardiology and critical care procedures. Biosensors is well-positioned to emerge as a leader in drug-eluting stents, an evolving therapy that is rapidly gaining market share from traditional therapies such as bare-metal stenting and open-heart surgery. Biosensors has internally developed technology to address each component of a drug-eluting stent system, including a stent, a stent delivery catheter, a biodegradable polymer and a proprietary antirestenotic drug. It is pursuing three separate drug-eluting stent programs, *BioMatrix*[®], *Axxion*[™], and *BioMatrix*[®] Freedom[™], a polymer-free drug-eluting stent, and has licensed aspects of its drug-eluting stent technology to four companies.

Forward Looking Statements

Certain statements herein include forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements generally can be identified by the use of forward-looking terminology, such as "may," "will," "expect," "intend," "estimate," "anticipate," "believe," "project" or "continue" or the negative thereof or other similar words. All forward-looking statements involve risks and uncertainties, including, but not limited to, customer acceptance and market share gains, competition from companies that have greater financial resources; introduction of new products into the marketplace by competitors; successful product development; dependence on significant customers; the ability to recruit and retain quality employees as Biosensors grows; and economic and political conditions globally. Actual results may differ materially from those discussed in, or implied by, the forward-looking statements. The forward-looking statements speak only as of the date of this release and Biosensors assumes no duty to update them to reflect new, changing or unanticipated events or circumstances.